Cohero Health has received FDA 510(k) clearance for its smart spirometer. The Bluetooth-enabled device measures critical lung function with comparable accuracy to clinical-grade spirometers, and beams the data collected to a connected smartphone or tablet.
The New York City-based company has been using the spirometer as part of its medication adherence tracking platform in a pilot at Mount Sinai Medical Center. By using it in combination with an inhaler sensor, Cohero is able to go beyond simple inhaler usage tracking, by making connections between inhaler usage and lung function.
Cohero’s spirometer is more accurate than a peak-flow meter, as it can track Forced Vital Capacity (FVC) and Forced Expiratory Volume (FEV1), the speed and volume of breath over time. In comparison, peak-flow meters can only track maximum speed of exhalation.
The smart spirometer works with Cohero’s pediatric (AsthmaHero) and adult (BreatheSmart) mobile apps to log and provide feedback on results. Both applications offer medication reminders, and can track the use of maintenance and rescue medication via inhaler sensors. The software is then able to track and analyze the effects of maintenance and rescue medication use, along with external triggers, on lung function.
Cohero’s early pilot results have shown a 250 percent increase in medication adherence, and 100 percent reduction in hospitalizations. The company now plans to launch additional pilots ahead of full commercial launch later this year.